Online telehealth company Hims and Hers Health is launching its weight-loss membership and treatment plans in the United ...

The move into the UK weight-loss category has been facilitated by the acquisition earlier this year of Zava, a London-based ...

Novo Nordisk enters the final stretch of 2025 looking almost unrecognizable from the market darling it was just months ago.

As competitive as the obesity drug market has become, Novo Nordisk's decision to slash the prices of its GLP-1 agonist drugs could put it back on the right track. While profit margins may slip due to ...

Online telehealth company Hims and Hers Health HIMS.N is launching its weight-loss membership and treatment plans in the UK ...

One of largest U.S. telehealth providers expects to ride wave of exploding demand for weight-loss drug semaglutide when it ...

Hims and Hers first announced its expansion into Canada in early July, taking the opportunity as Danish pharmaceutical giant ...

The dramatic stock slump, which puts Novo Nordisk at a historically cheap valuation, reflects investor concern over future sales growth and competition, particularly from rival Eli Lilly & Co.

Hims Hers Health Inc (NYSE:HIMS) stock fell 4.4% Wednesday after U.S. lawmakers introduced legislation that could ...

Hims & Hers Health stock has seen its fair value estimate trimmed from about $46.00 to roughly $44.36 per share, even as analysts grow more optimistic about its long term revenue trajectory. Stronger ...

What To Know: The weakness appears linked to Novo Nordisk’s decision to slash the U.S. self-pay price of its popular GLP-1 drugs, Wegovy and Ozempic, from $499 to $349 per month, intensifying pressure ...